

Question for written answer E-004090/2025
to the Commission
Rule 144
Nicolás González Casares (S&D)

Subject: The risks to access and the cost of medicines as a result of the price war declared by US President Donald Trump

As a result of President Trump's executive order on drug prices – which presented pharmaceutical companies with an ultimatum to increase drug prices in third countries – and the threat of tariffs, several European companies have announced new investments in the United States, leading to a reconsideration and delay of planned investments in Europe.

This context could be exploited by some pharmaceutical companies to pressure the EU and negotiate higher drug prices, which would have serious consequences, including an excessive increase in pharmaceutical spending, a deterioration in the sustainability of our healthcare systems and a real risk of limited access to medicines in some Member States.

1. Has the Commission therefore considered monitoring medicine prices to supervise and, if necessary, mitigate the impact of these measures?
2. Has the Commission considered launching an observatory to monitor the pharmaceutical market?
3. Is the Commission considering using the anti-coercion instrument to protect the internal market from the competitive effects of this hostile policy?

Submitted: 16.10.2025